Building a ctDNA-Based Model to Predict Survival & Outperform Radiographic Imaging for Differentiating between Chemo-Immunotherapy Combinations in Early Phase Clinical Trials
Time: 12:30 pm
day: Day One Track B AM
Details:
• Assessing ctDNA across longitudinal time points in a randomized Ph III study comparing chemotherapy-immunotherapy combinations
• Using machine learning in a training/testing framework to jointly model multiple ctDNA metrics to predict overall survival
• Validating model utility for identifying high-risk patients in an external validation cohort with a different ctDNA assay
• Demonstrating model utility in clinical drug development as an early endpoint to detect differences in overall survival between treatment arms
